Showing results (171-180 of 199) with videos related to
Sort By:
Pageof 20
Cancer Chemotherapy and Pharmacology|September 6, 2000
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)N Pavlidis, S Aamdal, A Awada, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2006
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumoursH Dumez, A Awada, M Piccart, et al.Breast Cancer Research and Treatment|December 16, 2003
Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancerN Bossard, F Descotes, A G Bremond, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of CancerA Hamilton, L Biganzoli, R Coleman, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trialP M Specenier, E Remenar, J Buter, et al.Investigational New Drugs|September 18, 1998
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignanciesH A Burris, E Raymond, A Awada, et al.British Journal of Cancer|November 3, 2011
TYRP1 mRNA expression in melanoma metastases correlates with clinical outcomeF Journe, H Id Boufker, L Van Kempen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-overR Paridaens, L Biganzoli, P Bruning, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2003
Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancerX Pivot, A Awada, D Gedouin, et al.European Journal of Cancer (Oxford, England : 1990)|September 30, 2008
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)C M L van Herpen, L D Locati, J Buter, et al.Pageof 20